Although nausea and vomiting (NV) are common complaints among individuals with terminal illness, there are few studies evaluating the magnitude of this disabling syndrome. Most research has emphasized chemotherapy-induced emesis, however, Reuben and Mor’ analyzed National Hospice Study data 2 and noted NV in 62 percent of patients with advanced malignancy during the last two months of life. In addition, NV was observed more frequently in women, persons younger than 65 years of age, and patients with stomach and breast cancer Lamentably, physicians were less likely to prescribe antiemetics in the elderly and inpatients with an impaired level of awareness.
With such a paucity of studies on NV in terminally-ill patients, there is frequent confusion regarding the etiology of emesis and the selection of appropriate antiemetics. This article will review the syndrome of N1 and discuss available drug regimens.
Get full access to this article
View all access options for this article.
References
1.
Reuben DB, Mor V: Nausea and vomiting in terminal cancer patients. Arch Intern Med, 1986;146:2021-2023.
2.
Greer DS, Mor V.Sherwood S, et al: National hospice study analysis plan. J Chronic Dis, 1983;36:737-780.
3.
Borison H, Wang SC: Functioning localization of central coordinating mechanisms for emesis in cats. J Neurophysiol, 1949;12:305-313.
4.
Craig JB, Powell BL: Review: The management of nausea and vomiting in clinical oncology. Am J Med Sci, 1987;293:34-44.
5.
Marin J, Ibanez MC, Arribas S: Therapeutic management of nausea and vomiting. Gen Pharmacol, 1990;21:1-10.
6.
Graves T: Emesis as a complication of cancer chemotherapy: Pathophysiology, importance, and treatment. Pharmacotherapy, 1992;12:337-345.
7.
Grunberg SM, Hesketh PJ: Control of chemotherapy-induced emesis. N Engl J Med, 1993;329:1790-1796.
8.
Allan SG:Emesis in the patient with advanced cancer. Palliat Med, 1988;2:89-100.
9.
Hogan CM: Advances in the management of nausea and vomiting. Nus Clin N Am, 1990;25:475-497.
10.
Allan SG: Nausea and vomiting. In Doyle D, Hanks GWC, MacDonald N (eds.): Oxford Textbook of Palliative Medicine. Oxford, Oxford University Press, 1993:282-290.
11.
Grunberg S.Nausea and vomiting induced by chemotherapeutic agents. Compr Ther, 1991;17:39-43.
12.
Carpenter DO:Neural mechanisms of emesis. Can J Physiol Pharmacol, 1990;68:230-236.
13.
Miller AD, Wilson VJ: “Vomiting center” reanalyzed: An electrical stimulation study. Brain Res, 1983;270:154-158.
14.
Lee M, Feldman M: Nausea and vomiting. In Sleisenger MB, Fonltran JS (eds.):Gastrointestinal Disease: Pathophysiology/Diagnosis/Management, Fifth Edition. Philadelphia, WB Saunders, 1993:509-523.
15.
Bradley PB, Engel G, Feniuk W, et al: Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology, 1986;25:563-576.
16.
Higgins GA, Kilpatrick GJ, Bunce KT, et al: 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin induced emesis in the ferret. Br J Pharmacol, 1989;97:247-255.
17.
Cooke CE, Mehra IV: Oral ondansetron for preventing nausea and vomiting. Am J Hosp Pharm, 1994;51:762-771
18.
Hesketh PJ, Gandara DR: Serotonin antagonists: A new class of antiemetic agents. J Nail Cancer Inst. 1991;83:613-620.
19.
Richardson BP, Engel G, Donatsch P.et al: Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature, 1985;316:126-131
20.
Fozaiti JR: Neumnal 5-HT receptors in the periphery. Neuropharmacology, 1984;23:1473-1486
21.
Dunbar AW, McCleliand CM, Sanger GJ: BRL 24924: A stimulant of gut motility which is also a potent antagonist of the von-Bezold-Jarischreflexin anesthetized rats. Br J Pharmacol, 1986;88:319.
22.
Enck RE, Hogan CM: Management of nausea and vomiting. Am J Hospice Care, 1987;4:17-19.
23.
Lichter I: Results of antiemetic management in terminal illness. J Palliat care, 1993;9:19-21.
24.
Leslie RA, Thejomayen SM, Murphy KM: The neuropharmacology of emesis: The role of receptors in neuromodulation of nausea and vomiting. Can J Physiol Pharmacol, 1990;68:279-288
25.
Sanger GJ: New antiemetic drugs. Can JPhysiol Pharmacol, 1990;68:314-328.
26.
Ventafridda V, Ripamonti C, Caraceni A, et al: The management of inoperable gastrointestinal obstruction in terminal cancer patients, Tumori, 1990;76:389-393.
Rich WMR, Abdulhayoghu G, DiSaia PJ: Methylprndnisolone an antiemetic during cancer chemotherapy—a pilot study. Gynecol Oncol, 1980;9:193-198.
29.
Livrea P.Trojano M, Simone IL, et al: Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. J Neurol, 1985;231:336-339.
30.
Bowcock SJ, Stockdale AD, Bolton JAR, et al: Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy. BMJ, 1979;288:1879.
31.
Enck RE: The Medical Care of Terminally Ill Patients. Baltimore, Johns Hopkins Press, 1994:17.
32.
Physician’s 1990 Drug Handbook: Springhouse, PA, Springhouse Corporation, 1990:575-577.
33.
Oliver DJ: The use of the syringe driver in terminal care. Br J Clin Pharmacol, 1985;20:515-516.
34.
Storey P.Hill HH, St. Louis RH, Tarver BE: Subcutaneous infusions for control of cancer symptoms. J Pain Symptom Manage, 1990;5:33-41
35.
Tortorice PV, O’Connell MB: Management of chemotherapy induced nausea and vomiting. Pharmacotherapy, 1990;10:129-145
36.
Physician’s 1990 Drug Handbook: Springhouse, PA, Springhouse Corporation, 1990:374.
37.
Kris MG, Tyson LB, Gralla RI, et al.: Extra pyramidal reactions with high-dose metoclopramide. N Engl J Med, 1983;309:433-434
38.
Kris MG, Tyson LB. Clark RA, et al.: Oral ondansetron for the control of delayed emesis after cisplatin. Cancer, 1992;70:1012-1016.
39.
Jones LA, Hill AS, Soukop M, et al.: Comparison of dexamethasone and on dansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet, 1991;338:483-487.
40.
Carmichael J, Cantwell BMJ, Edwards CM, et al.: A phamiacokinetic study of granisetron (BRL43694A), a selective 5-HT3 receptor antagonist: Correlation with antiemetic response. Cancer Chemother Pharmacol, 1989;24:45-49.
41.
Cupissol DR, Serrou B, Caubel M: The efficacy of granisetron as aprophylactic antiemetic and intervention agentin high-dose cisplatin-induced emesis. Eur J Cancer, 1990;26:S23-S27.
42.
Andrews PLR: The pharmacologic profile of granisetron (Kytril). Sem Oncol1994;21 (Suppl):3-9.
43.
Drugs for vomiting caused by cancer chemotherapy. Med Letter, 1993;35:124-126.
44.
Granisetron to prevent vomiting after cancer chemotherapy. Med Letter, 1994;36:61-62.
45.
Jacox A, Can DB, Payne R, et al.: Management of Cancer Pain. Clinical Practice Guideline No. 9. AHCPR Publication No. 94-0592. Rockville, MD. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, March, 1994:242-245.
